Central Retinal Vein Occlusion
In Case You Missed…Advancing Outcomes in Retinal Disease
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Clinical Trial Updates in nAMD, DME, RVO, MacTel, and GA Management
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; Neurotech Pharmaceuticals, Inc.; Astellas; EyePoint Pharmaceuticals, Inc.; Opthea Ltd.; Topcon Healthcare, Inc.; Outlook Therapeutics; REGENXBIO Inc.; Ocuphire Pharma; and Carl Zeiss Meditec, Inc.
Ip recounts top findings from SCORE2
WAILEA, Hawaii — Considering bevacizumab was found to be noninferior to aflibercept with respect to visual acuity in the SCORE2 trial, the incremental cost-effectiveness ratio is “unfavorable,” Michael S. Ip, MD, said at Retina 2021.
Woman presents with unilateral blurred vision
A 71-year-old Native American female presented with a chief complaint of constant blurred vision at distance and near in the right eye, which began 2 weeks ago.